Volume 11, Issue 3 (12-2023)
Jorjani Biomed J 2023, 11(3): 18-24 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Marefati N, Ghoshooni H, mahabadi M. Investigating the Role of ACE2 Receptors in the Rate of COVID-19 Infectivity in Smokers and Opioid Abusers: A Review. Jorjani Biomed J 2023; 11 (3) :18-24
URL: http://goums.ac.ir/jorjanijournal/article-1-969-en.html
URL: http://goums.ac.ir/jorjanijournal/article-1-969-en.html
1- Department of Physiology and Medical Physics, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
2- Department of Medical Microbiology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
3- Department of Medical Microbiology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran ,mostafa.m1@gmail.com
2- Department of Medical Microbiology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
3- Department of Medical Microbiology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran ,
Abstract: (1048 Views)
It seems necessary to understand the association of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), with its entering bronchoalveolar and brain cells, which have a high concentration of angiotensin-converting enzyme 2 (ACE2). Although the virus infects healthy people, the rate of infection and mortality is higher and significant in vulnerable people, such as drug users and addicts who have acute and chronic respiratory disease. It also places a heavy economic burden on families and societies around the world. Thus, researchers are aiming to provide prevention and treatment strategies to people at risk. The purpose of the present study was to collect studies on the rate of infection with coronavirus in people who abuse drugs. Besides, the role of the ACE2 receptor as a key factor in coronavirus infectivity in these people was investigated. Our narrative review on the relationship between COVID-19 and opioid abuse and smoking, with consideration of ACE2's role, contains original and human studies. According to the results of the current study, those who smoke or are dependent on opioids are much more likely to experience COVID-19-related respiratory side effects or even pass away.
Keywords: Coronavirus, COVID-19, Opioid-Related Disorders, Cigarette smoking, ACE2 Protein, Cytokine Release Syndrome
Type of Article: Review Article |
Subject:
Health
Received: 2023/06/16 | Accepted: 2023/10/15 | Published: 2024/04/30
Received: 2023/06/16 | Accepted: 2023/10/15 | Published: 2024/04/30
References
1. Hamed SM, Elkhatib WF, Khairalla AS, Noreddin AM. Global dynamics of SARS-CoV-2 clades and their relation to COVID-19 epidemiology. Sci Rep. 2021;11(1):8435. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett T-L, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55(5):2000688. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. Meftahi GH, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging". Inflamm Res. 2020;69(9):825-39. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Cai G, Bossé Y, Xiao F, Kheradmand F, Amos CI. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;201(12):1557-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Lapperre TS, Postma DS, Gosman MM, Snoeck-Stroband JB, ten Hacken NH, Hiemstra PS, et al. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax. 2006;61(2):115-21. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Mehta S, Parmar N, Kelleher M, Jolley CJ, White P, Durbaba S, et al. COPD and asthma in patients with opioid dependency: a cross-sectional study in primary care. NPJ Prim Care Respir Med. 2020;30(1):4. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Vozoris NT, Wang X, Fischer HD, Bell CM, O'Donnell DE, Austin PC, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2016;48(3):683-93. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Park J-E, Jung S, Kim A. MERS transmission and risk factors: a systematic review. BMC Public Health. 2018;18(1):574. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004;164(20):2206-16. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Chen YH, Wu KL, Tsai MT, Chien WH, Chen ML, Wang Y. Methadone enhances human influenza A virus replication. Addict Biol. 2017;22(1):257-71. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 2020;18:20. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Althobaiti YS, Alzahrani MA, Alsharif NA, Alrobaie NS, Alsaab HO, Uddin MN. The possible relationship between the abuse of tobacco, opioid, or alcohol with COVID-19. InHealthcare (Basel). 2020;9(1):2. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Kashyap VK, Dhasmana A, Massey A, Kotnala S, Zafar N, Jaggi M, et al. Smoking and COVID-19: Adding Fuel to the Flame. Int J Mol Sci. 2020;21(18):6581. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Lin Z. Mechanisms for substance use disorders in COVID-19. Mol Psychiatry. 2021;26(9):4568-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. Inflam Res. 2008;57(11):497-503. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Mallet J, Dubertret C, Le Strat Y. Addictions in the COVID-19 era: current evidence, future perspectives a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2021;106:110070. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Dubey MJ, Ghosh R, Chatterjee S, Biswas P, Chatterjee S, Dubey S. COVID-19 and addiction. Diabetes Metab Syndr. 2020;14(5):817-23. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Saeedi M, Omrani-Nava V, Maleki I, Hedayatizadeh-Omran A, Ahmadi A, Moosazadeh M, et al. Opium addiction and COVID-19: truth or false beliefs. Iran J Psychiatry Behav Sci. 2020;14(2):e103509. [View at Publisher] [DOI] [Google Scholar]
19. World Health Organization. WHO report on the global tobacco epidemic, 2008: the MPOWER package. World Health Organization; 2008. [View at Publisher] [Google Scholar]
20. Elisia I, Lam V, Cho B, Hay M, Li MY, Yeung M, et al. The effect of smoking on chronic inflammation, immune function and blood cell composition. Sci Rep. 2020;10(1):19480. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Boulet LP, Catherine L, Francine A, Guy C, Descary MC, Deschesnes F. Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. Chest. 2006;129(3):661-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Rennard SI. Cigarette smoke in research. Am J Respir Cell Mol Biol. 2004;31(5):479-80. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. KuKanich B, Wiese AJ. Opioids. Vet Anaesth Analg. 2015:207-26. [View at Publisher] [DOI] [Google Scholar]
24. Lord JA, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: multiple agonists and receptors. Nature. 1977;267(5611):495-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
25. Holden JE, Jeong Y, Forrest JM. The endogenous opioid system and clinical pain management. AACN Clin Issues. 2005;16(3):291-301. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors. Trends Neurosci. 1988;11(7):308-14. [View at Publisher] [DOI] [PMID] [Google Scholar]
27. Krajnik M, Schäfer M, Sobański P, Kowalewski J, Bloch-Bogusławska E, Zylicz Z, et al. Local pulmonary opioid network in patients with lung cancer: a putative modulator of respiratory function. Pharmacol Rep. 2010;62(1):139-49. [View at Publisher] [DOI] [PMID] [Google Scholar]
28. Tahamtan A, Tavakoli-Yaraki M, Salimi V. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients. Expert Rev Respir Med. 2020;14(10):965-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
29. Cismaru CA, Cismaru GL, Nabavi SF, Ghanei M, Burz CC, Nabavi SM, et al. Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID‐19. J Cell Mol Med. 2021;25(1):591-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
30. Becker WC, Fiellin DA. When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med. 2020;173(1):59-60. [View at Publisher] [DOI] [PMID] [Google Scholar]
31. Lambert DG. Opioids and the COVID-19 pandemic: does chronic opioid use or misuse increase clinical vulnerability? Br J Anaesth. 2020;125(4):e382-3. [View at Publisher] [DOI] [PMID] [Google Scholar]
32. Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2021;26(1):30-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
33. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). J Clin Med. 2020;9(3):841. [View at Publisher] [DOI] [PMID] [Google Scholar]
34. Hung Y-H, Hsieh W-Y, Hsieh J-S, Liu C, Tsai C-H, Lu L-C, et al. Alternative roles of STAT3 and MAPK signaling pathways in the MMPs activation and progression of lung injury induced by cigarette smoke exposure in ACE2 knockout mice. Int J Biol Sci. 2016;12(4):454-65. [View at Publisher] [DOI] [PMID] [Google Scholar]
35. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
36. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
37. Rivellese F, Prediletto E. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia. Autoimmun Rev. 2020;19(6):102536. [View at Publisher] [DOI] [PMID] [Google Scholar]
38. Dalan R, Bornstein SR, El-Armouche A, Rodionov RN, Markov A, Wielockx B, et al. The ACE-2 in COVID-19: foe or friend? Horm Metab Res. 2020;52(5):257-63. [View at Publisher] [DOI] [PMID] [Google Scholar]
39. Miyara M, Tubach F, Pourcher V, Morelot-Panzini C, Pernet J, Haroche J, et al. Low rate of daily active tobacco smoking in patients with symptomatic COVID-19. Qeios Published online. 2020. [View at Publisher] [DOI] [Google Scholar]
40. Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8(11):1106-20. [View at Publisher] [DOI] [PMID] [Google Scholar]
41. Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, et al. SARS‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39(10):e105114. [View at Publisher] [DOI] [PMID] [Google Scholar]
42. Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, Pickles RJ. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol. 2005;79(24):15511-24. [View at Publisher] [DOI] [PMID] [Google Scholar]
43. Osan JK, Talukdar SN, Feldmann F, DeMontigny BA, Jerome K, Bailey KL, et al. Goblet Cell Hyperplasia Increases SARS-CoV-2 Infection in COPD. bioRxiv. 2020:2020.11.11.379099.[Preprint] [View at Publisher] [DOI] [PMID] [Google Scholar]
44. Jankun J. COVID-19 pandemic; transmembrane protease serine 2 (TMPRSS2) inhibitors as potential drugs. Translation: The University of Toledo Journal of Medical Sciences. 2020;7:1-5. [View at Publisher] [DOI] [Google Scholar]
45. Voinsky I, Gurwitz D. Smoking and COVID‐19: Similar bronchial ACE2 and TMPRSS2 expression and higher TMPRSS4 expression in current versus never smokers. Drug Dev Res. 2020;81(8):1073-80. [View at Publisher] [DOI] [PMID] [Google Scholar]
46. Hao S, Ning K, Kuz CA, Vorhies K, Yan Z, Qiu J. Long-Term Modeling of SARS-CoV-2 Infection of In Vitro Cultured Polarized Human Airway Epithelium. mbio. 2020;11(6):e02852-20. [View at Publisher] [DOI] [PMID] [Google Scholar]
47. Wu C, Zheng M, Yang Y, Gu X, Yang K, Li M, et al. Furin: A Potential Therapeutic Target for COVID-19. iScience. 2020;23(10):101642. [View at Publisher] [DOI] [PMID] [Google Scholar]
48. Matusiak M, Schürch CM. Expression of SARS-CoV-2 entry receptors in the respiratory tract of healthy individuals, smokers and asthmatics. Respir Res. 2020;21(1):252. [View at Publisher] [DOI] [PMID] [Google Scholar]
49. Parry AH, Wani AH, Yaseen M. Neurological dysfunction in coronavirus disease-19 (COVID-19). Acad Radiol. 2020;27(9):1329-30. [View at Publisher] [DOI] [PMID] [Google Scholar]
50. Clarke NE, Belyaev ND, Lambert DW, Turner AJ. Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress. Clin Sci (Lond). 2014;126(7):507-16. [View at Publisher] [DOI] [PMID] [Google Scholar]
51. Ferguson D, Koo JW, Feng J, Heller E, Rabkin J, Heshmati M, et al. Essential role of SIRT1 signaling in the nucleus accumbens in cocaine and morphine action. J Neurosci. 2013 Oct 9;33(41):16088-98. [View at Publisher] [DOI] [PMID] [Google Scholar]
52. Conti-Fine BM, Navaneetham D, Lei S, Maus AD. Neuronal nicotinic receptors in non-neuronal cells: new mediators of tobacco toxicity? Eur J Pharmacol. 2000;393(1-3):279-94. [View at Publisher] [DOI] [PMID] [Google Scholar]
53. Wang Y, Pereira E, Maus A, Ostlie N, Navaneetham D, Lei S, et al. Human bronchial epithelial and endothelial cells express α7 nicotinic acetylcholine receptors. Mol Pharmacol. 2001;60(6):1201-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
54. Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. 2018;315(5):R895-906. [View at Publisher] [DOI] [PMID] [Google Scholar]
55. Farsalinos K, Eliopoulos E, Leonidas DD, Papadopoulos GE, Tzartos S, Poulas K. Nicotinic cholinergic system and COVID-19: in silico identification of an interaction between SARS-CoV-2 and nicotinic receptors with potential therapeutic targeting implications. Int J Mol Sci. 2020;21(16):5807. [View at Publisher] [DOI] [PMID] [Google Scholar]
56. Farsalinos K, Niaura R, Le Houezec J, Barbouni A, Tsatsakis A, Kouretas D, et al. Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep. 2020;7:658-63. [View at Publisher] [DOI] [PMID] [Google Scholar]
57. Sifat AE, Nozohouri S, Villalba H, Vaidya B, Abbruscato TJ. The Role of Smoking and Nicotine in the Transmission and Pathogenesis of COVID-19. J Pharmacol Exp Ther. 2020;375(3):498-509. [View at Publisher] [DOI] [PMID] [Google Scholar]
58. Russo P, Bonassi S, Giacconi R, Malavolta M, Tomino C, Maggi F. COVID-19 and smoking: is nicotine the hidden link? Eur Respir J. 2020;55(6):2001116. [View at Publisher] [DOI] [PMID] [Google Scholar]
59. Li G, He X, Zhang L, Ran Q, Wang J, Xiong A, et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun. 2020;112:102463. [View at Publisher] [DOI] [PMID] [Google Scholar]
60. Maremanda KP, Sundar IK, Li D, Rahman I. Age-dependent assessment of genes involved in cellular senescence, telomere, and mitochondrial pathways in human lung tissue of smokers, COPD, and IPF: Associations With SARS-CoV-2 COVID-19 ACE2-TMPRSS2-Furin-DPP4 Axis. Front Pharmacol. 2020;11:102463. [View at Publisher] [DOI] [PMID] [Google Scholar]
61. Vleeming W, Rambali B, Opperhuizen A. The role of nitric oxide in cigarette smoking and nicotine addiction. Nicotine Tob Res. 2002;4(3):341-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
62. Coleman JW. Nitric oxide in immunity and inflammation. Int Immunopharmacol. 2001;1(8):1397-406. [View at Publisher] [DOI] [PMID] [Google Scholar]
63. Martel J, Ko Y-F, Young JD, Ojcius DM. Could nasal nitric oxide help to mitigate the severity of COVID-19? Microbes Infect. 2020;22(4-5):168-71. [View at Publisher] [DOI] [PMID] [Google Scholar]
64. Dias Junior CA, Cau SBdA, Tanus Santos JE. Role of nitric oxide in the control of the pulmonary circulation: physiological, pathophysiological, and therapeutic implications. J bras pneumol. 2008;34(6):412-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
65. Boskabady M, Marefati N, Farkhondeh T, Shakeri F, Farshbaf A, Boskabady MH. The effect of environmental lead exposure on human health and the contribution of inflammatory mechanisms, a review. Environ Int. 2018;120:404-20. [View at Publisher] [DOI] [PMID] [Google Scholar]
66. Barnes PJ, Shapiro SD, Pauwels R. Chronic obstructive pulmonary disease: molecular and cellularmechanisms. Eur Respir J. 2003;22(4):672-88. [View at Publisher] [DOI] [PMID] [Google Scholar]
67. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res. 2006;7(1):53. [View at Publisher] [DOI] [PMID] [Google Scholar]
68. Imai K, Mercer B, Schulman L, Sonett J, D'Armiento J. Correlation of lung surface area to apoptosis and proliferation in human emphysema. Eur Respir J. 2005;25(2):250-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
69. Serota DP, Barocas JA, Springer SA. Infectious complications of addiction: a call for a new subspecialty within infectious diseases. Clin Infect Dis. 2020;70(5):968-72. [View at Publisher] [DOI] [PMID] [Google Scholar]
70. Wei Y, Shah R. Substance use disorder in the COVID-19 pandemic: a systematic review of vulnerabilities and complications. Pharmaceuticals (Basel). 2020;13(7):155. [View at Publisher] [DOI] [PMID] [Google Scholar]
71. Kienbaum P, Thurauf N, Michel MC, Scherbaum N, Gastpar M, Peters J. Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after [micro sign]-opioid receptor blockade in opioid-addicted patients during barbiturate-induced anesthesia for acute detoxification. Anesthesiology. 1998;88(5):1154-61. [View at Publisher] [DOI] [PMID] [Google Scholar]
72. Porubsky S, Kuppe C, Maier T, Birk H-W, Wörnle M, Moeller MJ, et al. Renal lipidosis in patients enrolled in a methadone substitution program. Arch Pathol Lab Med. 2014;138(5):689-93. [View at Publisher] [DOI] [PMID] [Google Scholar]
73. Gibson A, Randall D, Degenhardt L. The increasing mortality burden of liver disease among opioid‐dependent people: cohort study. Addiction. 2011;106(12):2186-92. [View at Publisher] [DOI] [PMID] [Google Scholar]
74. Kuczeriszka M, Lipkowski AW, Sadowski J, Kompanowska-Jezierska E. An endomorphine analog ([d-Ala2]-Endomorphin 2, TAPP) lowers blood pressure and enhances tissue nitric oxide in anesthetized rats. Pharmacol Rep. 2016;68(3):616-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
75. Dubey MJ, Ghosh R, Chatterjee S, Biswas P, Chatterjee S, Dubey S. COVID-19 and addiction. Diabetes Metab Syndr. 2020;14(5):817-23. [View at Publisher] [DOI] [PMID] [Google Scholar]
76. Dunlop A, Lokuge B, Masters D, Sequeira M, Saul P, Dunlop G, et al. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduct J. 2020;17(1):26. [View at Publisher] [DOI] [PMID] [Google Scholar]
77. Adams CD, Altshuler J, Barlow BL, Dixit D, Droege CA, Effendi MK, et al. Analgesia and Sedation Strategies in Mechanically Ventilated Adults with COVID‐19. Pharmacotherapy. 2020;40(12):1180-91. [View at Publisher] [DOI] [PMID] [Google Scholar]
78. Steffens C, Sung M, Bastian LA, Edelman EJ, Brackett A, Gunderson CG. The association between prescribed opioid receipt and community-acquired pneumonia in adults: a systematic review and meta-analysis. J Gen Intern Med. 2020;35(11):3315-22. [View at Publisher] [DOI] [PMID] [Google Scholar]
79. Eisenstein TK. The role of opioid receptors in immune system function. Front Immunol. 2019;10:2904. [View at Publisher] [DOI] [PMID] [Google Scholar]
80. Hussey HH, Katz S. Infections resulting from narcotic addiction: report of 102 cases. Am J Med. 1950;9(2):186-93. [View at Publisher] [DOI] [PMID] [Google Scholar]
81. Eisenstein TK, Rahim RT, Feng P, Thingalaya NK, Meissler JJ. Effects of opioid tolerance and withdrawal on the immune system. J Neuroimmune Pharmacol. 2006;1(3):237-49. [View at Publisher] [DOI] [PMID] [Google Scholar]
82. Kemp HI, Corner E, Colvin LA. Chronic pain after COVID-19: implications for rehabilitation. Br J Anaesth. 2020;125(4):436-40. [View at Publisher] [DOI] [PMID] [Google Scholar]
83. Kiserud Y, Rosland JH. Lindring av truende kvelning hos døende pasienter med covid-19. Tidsskr Nor Laegeforen. 2020. [View at Publisher] [DOI] [Google Scholar]
84. Schimmel J, Manini AF. Opioid use disorder and COVID-19: biological plausibility for worsened outcomes. Subst Use Misuse. 2020;55(11):1900-1. [View at Publisher] [DOI] [PMID] [Google Scholar]
85. Madera-Salcedo IK, Cruz SL, Gonzalez-Espinosa C. Morphine decreases early peritoneal innate immunity responses in Swiss-Webster and C57BL6/J mice through the inhibition of mast cell TNF-α release. J Neuroimmunol. 2011;232(1-2):101-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
86. Wang J, Charboneau R, Balasubramanian S, Barke RA, Loh HH, Roy S. The immunosuppressive effects of chronic morphine treatment are partially dependent on corticosterone and mediated by the μ‐opioid receptor. J Leukoc Biol. 2002;71(5):782-90. [View at Publisher] [DOI] [PMID] [Google Scholar]
87. Nabati S, Asadikaram G, Arababadi MK, Shahabinejad G, Rezaeian M, Mahmoodi M, et al. The plasma levels of the cytokines in opium-addicts and the effects of opium on the cytokines secretion by their lymphocytes. Immunol Lett. 2013;152(1):42-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
88. Menzebach A, Hirsch J, Nöst R, Mogk M, Hempelmann G, Welters ID. Morphine inhibits complement receptor expression, phagocytosis and oxidative burst by a nitric oxide dependent mechanism. Anasthesiol Intensivmed Notfallmed Schmerzther. 2004;39(4):204-11. [View at Publisher] [DOI] [PMID] [Google Scholar]
89. Wang J, Barke RA, Charboneau R, Loh HH, Roy S. Morphine negatively regulates interferon-γ promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J Biol Chem. 2003;278(39):37622-31. [View at Publisher] [DOI] [PMID] [Google Scholar]
90. Hudzik B, Nowak J, Zubelewicz-Szkodzinska B. Consideration of immunomodulatory actions of morphine in COVID-19-Short report. Eur Rev Med Pharmacol Sci. 2020;24(24):13062-4. [View at Publisher] [DOI] [PMID] [Google Scholar]
91. Hsiao P-N, Chang M-C, Cheng W-F, Chen C-A, Lin H-W, Hsieh C-Y, et al. Morphine induces apoptosis of human endothelial cells through nitric oxide and reactive oxygen species pathways. Toxicology. 2009;256(1-2):83-91. [View at Publisher] [DOI] [PMID] [Google Scholar]
92. Liu H-C, Anday JK, House SD, Chang SL. Dual effects of morphine on permeability and apoptosis of vascular endothelial cells: morphine potentiates lipopolysaccharide-induced permeability and apoptosis of vascular endothelial cells. J Neuroimmunol. 2004;146(1-2):13-21. [View at Publisher] [DOI] [PMID] [Google Scholar]
93. Ghobadian R, Khaleghzadeh-Ahangar H. Smoke, nicotine, opioids, and cannabinoids effects on the ACE2 protein level and possibility of COVID-19 infection: Suggesting potential preventives and therapeutics. Acta Fac Med Naiss. 2022;39(3):285-95. [View at Publisher] [DOI] [Google Scholar]
94. Dolati-Somarin A, Abd-Nikfarjam B. The reasons for higher mortality rate in opium addicted patients with COVID-19: a narrative review. Iran J Public Health. 2021;50(3):470-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
95. Jalodia R, Antoine D, Braniff RG, Dutta RK, Ramakrishnan S, Roy S. Opioid-Use, COVID-19 Infection, and Their Neurological Implications. Front Neurol. 2022;13:884216. [View at Publisher] [DOI] [PMID] [Google Scholar]
96. Fayazi HS, Naeimi A, Yaseri M, Khatibani SS. The Effect of Smoking and Opioid Consumption on the Severity of the Disease and Duration of Hospitalization in COVID-19 Patients. Acta Medica Bulgarica. 2023;50(1):34-40. [View at Publisher] [DOI] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
